Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What You Need To Know About These 4 Sinking Stocks

Page 1 of 2

The markets are up this morning thanks to positivity surrounding the strong earnings results of McDonald’s Corporation (NYSE:MCD), among other companies. Both the S&P 500 and NASDAQ Composite Index are up by about 1.5% in trading today. However not all stocks are feeling the market’s love this morning. Healthcare services stocks have had a particularly rough morning, while a variety of other stocks are sinking of their own accord. We’ll study four such stocks in this article and see why their shares are being passed off like hot potatoes.


First up is Valeant Pharmaceuticals Intl Inc (NYSE:VRX), the first of two stocks in this article that are top choices of activist investor Jeffrey Ubben (pictured above), whose top picks continue to lag in the short-term. The brutal run continues for Valeant, which is down by another 18.54% today after the Canadian pharmaceutical company was compared to Enron in a research report from short-selling firm Citron Research yesterday, which caused shares to sink by over 26%. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) defended its relationship with Philidor, which was questioned in the report, as well as its accounting practices, claiming they are sound. Nonetheless, the rebuttal has done nothing to stem the stock’s bleeding, as the once-red hot stock is now down by 32% year-to-date. Ubben held 14.99 million shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as of June 30.

Follow Valeant Pharmaceuticals International (NYSE:VRX)
Trade (NYSE:VRX) Now!

Whether elite hedge funds collectively like a stock or not is an important metric to consider, as these large investors show a great level of skill and expertise when it comes to picking stocks. Over the last few years equity hedge funds have trailed the market by a large margin, but that’s mostly due to their hedging and short positions, which perform poorly in a bull market. Their long positions performed far better, especially their small-cap picks, which have the potential to beat the market by 95 basis points per month on average, as our backtests showed. Our small-cap strategy involves imitating a portfolio of the 15 most popular small-cap picks among hedge funds and it has returned 102% since August 2012, beating the S&P 500 ETF (SPY) by over 53 percentage points (read more details here).

Ubben was also a major shareholder of American Express Company (NYSE:AXP), owning 11.10 million shares of the credit services company on June 30. Shares are down by 5.46% today after American Express Company (NYSE:AXP) reported underwhelming third quarter results after the markets closed on Wednesday. American Express Company (NYSE:AXP)’s EPS of $1.24 was $0.07 short of estimates, while its revenue of $8.19 billion was down by 1.4% year-over-year and missed estimates by $130 million. While the volume of U.S transactions was up by 7% year-over-year, the size of the transactions declined by 3%, partly due to lower gas charges at the pumps. Credit Suisse reiterated its ‘Underperform’ rating on the stock following the report, while cutting its price target to $71 from $74.

Follow American Express Co (NYSE:AXP)
Trade (NYSE:AXP) Now!

Two more of the day’s sinking stocks are analyzed on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!